A 12-month, longitudinal, intervention study examining a tablet protein substitute preparation in the management of tyrosinemia

IF 1.8 4区 医学 Q3 GENETICS & HEREDITY Molecular Genetics and Metabolism Reports Pub Date : 2024-07-16 DOI:10.1016/j.ymgmr.2024.101119
Anne Daly, Sharon Evans, Alex Pinto, Catherine Ashmore, Anita MacDonald
{"title":"A 12-month, longitudinal, intervention study examining a tablet protein substitute preparation in the management of tyrosinemia","authors":"Anne Daly,&nbsp;Sharon Evans,&nbsp;Alex Pinto,&nbsp;Catherine Ashmore,&nbsp;Anita MacDonald","doi":"10.1016/j.ymgmr.2024.101119","DOIUrl":null,"url":null,"abstract":"<div><p>Protein substitutes (PS) without tyrosine (Tyr) and phenylalanine (Phe), are an essential source of synthetic protein in the treatment of tyrosinemia (HT). In the UK, the only available protein substitutes for HT are Tyr/ Phe free amino acid liquid or powders or formulations based on glycomacropeptide (CGMP). A tablet Tyr/ Phe free amino acid supplement (AAT) has now been introduced. The aim of this two-part prospective, longitudinal intervention study was to assess the efficacy, acceptability, and tolerance of AAT in children aged &gt;8 years with HTI. Part 1: was a 28-day acceptability/ tolerance study, part 2, was a 12-month extension study examining efficacy of AAT. Anthropometry and blood Tyr/ Phe were assessed. All subjects were taking NTBC [2-(2-nitro-4-triflourothybenzoyl) cyclohexane-1, 3-dione] with a Tyr restricted diet. Eight subjects with HTI were recruited 4 boys, and 4 girls with a median age of 14.3y (range 10.4–17.3); 3 were Caucasian and 5 of Pakistani origin. The median (range) protein equivalent from PS was 60 g/d (50–60), natural protein 20 g/d (15–30), and NTBC 30 mg/d (25–80). No subjects were taking Phe supplements. Five (63%) subjects completed part 1, with 4 taking all their PS requirements as AAT. Subjects reported AAT were tasteless and had no odour. No adverse gastrointestinal symptoms were recorded, with two reporting improvements in abdominal discomfort. At 12 months, 4 subjects had a non-significant decrease in blood Tyr/ Phe compared to the 12 months pre-treatment. Median blood Tyr (μmol/ L) pre-intervention was 500 (320–590); and at 12 months, 450 (290–530). Median blood Phe (μmol/L) pre-intervention was 40 (30–40); and at 12 months 30 (30–50). Median height z scores remained unchanged, but there was a small decrease in weight z score (pre-study weight − 0.1 (−1.4 to1.1), 12 m − 0.3 (−1.4 to 1.3) and BMI (pre- study BMI 0.2 (−2 to 1.4), and 12 m, −0.1 (−2.5 to 1.5)).</p></div><div><h3>Conclusion</h3><p>AAT were useful for some adolescents with HTI who struggled with the taste and volume of conventional powdered and liquid PS.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":"40 ","pages":"Article 101119"},"PeriodicalIF":1.8000,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000727/pdfft?md5=46d4d0250df9d68ed9a9dbf97a32f975&pid=1-s2.0-S2214426924000727-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Genetics and Metabolism Reports","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2214426924000727","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Protein substitutes (PS) without tyrosine (Tyr) and phenylalanine (Phe), are an essential source of synthetic protein in the treatment of tyrosinemia (HT). In the UK, the only available protein substitutes for HT are Tyr/ Phe free amino acid liquid or powders or formulations based on glycomacropeptide (CGMP). A tablet Tyr/ Phe free amino acid supplement (AAT) has now been introduced. The aim of this two-part prospective, longitudinal intervention study was to assess the efficacy, acceptability, and tolerance of AAT in children aged >8 years with HTI. Part 1: was a 28-day acceptability/ tolerance study, part 2, was a 12-month extension study examining efficacy of AAT. Anthropometry and blood Tyr/ Phe were assessed. All subjects were taking NTBC [2-(2-nitro-4-triflourothybenzoyl) cyclohexane-1, 3-dione] with a Tyr restricted diet. Eight subjects with HTI were recruited 4 boys, and 4 girls with a median age of 14.3y (range 10.4–17.3); 3 were Caucasian and 5 of Pakistani origin. The median (range) protein equivalent from PS was 60 g/d (50–60), natural protein 20 g/d (15–30), and NTBC 30 mg/d (25–80). No subjects were taking Phe supplements. Five (63%) subjects completed part 1, with 4 taking all their PS requirements as AAT. Subjects reported AAT were tasteless and had no odour. No adverse gastrointestinal symptoms were recorded, with two reporting improvements in abdominal discomfort. At 12 months, 4 subjects had a non-significant decrease in blood Tyr/ Phe compared to the 12 months pre-treatment. Median blood Tyr (μmol/ L) pre-intervention was 500 (320–590); and at 12 months, 450 (290–530). Median blood Phe (μmol/L) pre-intervention was 40 (30–40); and at 12 months 30 (30–50). Median height z scores remained unchanged, but there was a small decrease in weight z score (pre-study weight − 0.1 (−1.4 to1.1), 12 m − 0.3 (−1.4 to 1.3) and BMI (pre- study BMI 0.2 (−2 to 1.4), and 12 m, −0.1 (−2.5 to 1.5)).

Conclusion

AAT were useful for some adolescents with HTI who struggled with the taste and volume of conventional powdered and liquid PS.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
一项为期 12 个月的纵向干预研究,考察了片剂蛋白替代制剂在治疗酪氨酸血症中的应用情况
不含酪氨酸(Tyr)和苯丙氨酸(Phe)的蛋白质替代品(PS)是治疗酪氨酸血症(HT)的重要合成蛋白质来源。在英国,治疗酪氨酸血症的蛋白质替代品只有不含酪氨酸/苯丙氨酸的氨基酸液剂、粉剂或基于糖化肽(CGMP)的制剂。现在,一种片剂不含 Tyr/ Phe 的氨基酸补充剂 (AAT) 已经问世。这项由两部分组成的前瞻性纵向干预研究旨在评估 AAT 对 8 岁 HTI 患儿的疗效、可接受性和耐受性。第一部分是为期28天的可接受性/耐受性研究,第二部分是为期12个月的延伸研究,考察AAT的疗效。对人体测量和血液酪氨酸/酪氨酸进行了评估。所有受试者都在服用 NTBC [2-(2-硝基-4-三氟乙基苯甲酰基)环己烷-1,3-二酮] 的同时限制酪氨酸饮食。招募的 8 名 HTI 受试者中有 4 名男孩和 4 名女孩,中位年龄为 14.3 岁(10.4-17.3 岁不等);其中 3 人是白种人,5 人是巴基斯坦人。来自 PS 的蛋白质当量中位数(范围)为 60 克/天(50-60),天然蛋白质为 20 克/天(15-30),NTBC 为 30 毫克/天(25-80)。没有受试者服用 Phe 补充剂。五名受试者(63%)完成了第一部分,其中四名受试者将其所需的 PS 全部作为 AAT 摄入。受试者报告说,AAT 无味,没有气味。没有记录到不良的胃肠道症状,其中两名受试者表示腹部不适有所改善。与治疗前 12 个月相比,4 名受试者 12 个月后的血液 Tyr/ Phe 下降不明显。干预前血液酪氨酸(μmol/L)的中位数为 500(320-590);12 个月时为 450(290-530)。干预前血液中位数 Phe(μmol/L)为 40(30-40),12 个月时为 30(30-50)。身高 z 评分中位数保持不变,但体重 z 评分略有下降(研究前体重 - 0.1(-1.4 至 1.1),12 个月时 - 0.3(-1.4 至 1.3))和体重指数(研究前体重指数为 0.2(-2 至 1.4),12 个月时为 -0.1(-2.5 至 1.5))。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Molecular Genetics and Metabolism Reports
Molecular Genetics and Metabolism Reports Biochemistry, Genetics and Molecular Biology-Endocrinology
CiteScore
4.00
自引率
5.30%
发文量
105
审稿时长
33 days
期刊介绍: Molecular Genetics and Metabolism Reports is an open access journal that publishes molecular and metabolic reports describing investigations that use the tools of biochemistry and molecular biology for studies of normal and diseased states. In addition to original research articles, sequence reports, brief communication reports and letters to the editor are considered.
期刊最新文献
D-glyceric aciduria due to GLYCTK mutation: Disease or non-disease? A case series of Cypriot patients with CblC defect: Clinical, biochemical and molecular characteristics A novel disease-causing variant associated with a milder phenotype of AARS2-related leukodystrophy — A case report Carbamoly-phosphate synthetase 1 (CPS1) deficiency: A tertiary center retrospective cohort study and literature review Impact of the Covid19 pandemic on health-related quality of life in patients with Fabry disease - implications for future care of patients with rare diseases
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1